Zhou J, Kumarasamy N
National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, Australia.
HIV Med. 2005 May;6(3):216-23. doi: 10.1111/j.1468-1293.2005.00292.x.
HIV disease progression has been well documented in Western populations. This study aimed to estimate the short-term risk of AIDS and death from the TREAT Asia HIV Observational Database (TAHOD), a prospective, multicentre cohort study in Asia and the Pacific region.
Prospective data were analysed to estimate short-term disease progression. Endpoints were defined as the time from study entry to diagnosis with AIDS or death. Antiretroviral treatment was fitted as a time-dependent variable. Predictors of disease progression were assessed using Cox proportional hazards models, and prognostic models were developed using Weibull models.
A total of 1260 patients with prospective follow-up data contributed 477 person-years of follow-up, during which 18 patients died and 34 were diagnosed with AIDS, a combined rate of 10.1 per 100 person-years. Compared with patients receiving antiretroviral treatment, patients not on treatment had a higher rate of disease progression (17.6 vs. 8.1 per 100 person-years, respectively). Baseline CD4 count was the strongest predictor of disease progression. Prognostic models, using either a baseline CD4 count as the sole marker or markers including baseline haemoglobin, AIDS-related symptoms and previous or current antiretroviral treatment, were successful at identifying patients at high risk of short-term disease progression.
Similar to the situation in Western countries, baseline CD4 count was the strongest predictor of short-term disease progression. Prognostic models based on readily available clinical data and haemoglobin level should be useful in estimating short-term clinical risk in HIV-infected patients in Asia and the Pacific region.
在西方人群中,HIV疾病进展已有充分记录。本研究旨在通过亚太地区HIV观察数据库(TAHOD)这一前瞻性多中心队列研究,评估艾滋病和死亡的短期风险。
分析前瞻性数据以估计短期疾病进展。终点定义为从研究入组到诊断为艾滋病或死亡的时间。抗逆转录病毒治疗作为一个随时间变化的变量纳入分析。使用Cox比例风险模型评估疾病进展的预测因素,并使用Weibull模型建立预后模型。
共有1260例具有前瞻性随访数据的患者,随访时间共计477人年,在此期间18例患者死亡,34例被诊断为艾滋病,综合发生率为每100人年10.1例。与接受抗逆转录病毒治疗的患者相比,未接受治疗的患者疾病进展率更高(分别为每100人年17.6例和8.1例)。基线CD4细胞计数是疾病进展最强的预测因素。使用基线CD4细胞计数作为唯一标志物或包括基线血红蛋白、艾滋病相关症状以及既往或当前抗逆转录病毒治疗等标志物的预后模型,成功识别出了短期疾病进展高风险患者。
与西方国家的情况类似,基线CD4细胞计数是短期疾病进展最强的预测因素。基于易于获得的临床数据和血红蛋白水平的预后模型,应有助于评估亚太地区HIV感染患者的短期临床风险。